Clinical trials: Buccal Cavity Cancer
Multiple Myeloma
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1 of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral ixazomib administered in combination with lenalidomide and low-dose…
- Trial name
- NCT01217957
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in United States
- Volunteers
- 65 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
The purpose of this study is to characterize the pharmacokinetics (what the body does to the study medication) of JNJ-38518168 at approximately steady-state (stable medication levels) after administration of multiple oral 30 mg…
- Trial name
- NCT01863784
- Testing
- JNJ-38518168
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
Safety and Efficacy of LCL161 in Patients With Solid Tumors
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
- Trial name
- NCT01098838
- Testing
- LCL161
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular, Biliary Tract Cancer
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement.
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Trial name
- NCT04338685
- Testing
- RO7119929, Tocilizumab
- Where
- 10 sites in United States, Denmark and 4 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Chronic Myeloid Leukemia
TGRX-678 Phase I Oral Pharmacokinetic Study
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
- Trial name
- NCT06697899
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Non-small Cell Lung Cancer
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT00530621
- Testing
- enzastaurin, pemetrexed
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Chronic Myelogenous Leukemia
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
- Trial name
- NCT04948333
- Testing
- ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD
- Where
- 48 sites in Argentina, Austria and 14 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Infertility, Female, Polycystic Ovary Syndrome
Antioxidant Supplement Associated With Oral Probiotics in Patients With PCOS in IVF
The aim of the study is to study the effect of an antioxidant food supplement associated with probiotics on the oocyte quality response, oxidative stress and microbiota function in an in vitro fertilization cycle in patients with…
- Trial name
- NCT04670393
- Testing
- FertyBiotic Woman Plus
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fertypharm
Advanced Solid Tumors
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally twice per week, every 28 days, to adult patients with advanced solid tumors who have…
- Trial name
- NCT00487058
- Testing
- Gimatecan
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Novartis
Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia
Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction
Background: Radiation can cause the parotid salivary glands to make less saliva (dry mouth). This can cause problems like infections and tooth decay. Researchers hope a new drug can help people with dry mouth caused by radiation.
- Conditions
- Squamous Cell Head and Neck Cancer, Radiation Induced Xerostomia, Salivary Hypofunction
- Trial name
- NCT02446249
- Testing
- AAV2hAQP1
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- MeiraGTx, LLC
Bone Marrow Diseases, Myelodysplastic Syndromes
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in patients with myelodysplastic syndromes.
- Conditions
- Bone Marrow Diseases, Myelodysplastic Syndromes, Hematologic Diseases, Bone Marrow Neoplasms
- Trial name
- NCT00113893
- Testing
- SCIO-469
- Volunteers
- 62 people
- Sponsor
- Scios, Inc.
Hematologic Malignancies
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy of TXA127 to reduce the incidence (Grade II-IV) of acute Graft-vs.-Host Disease (aGVHD) in adult subjects undergoing allogeneic peripheral blood stem cell transplantation…
- Trial name
- NCT01882387
- Testing
- TXA127
- Where
- 2 sites in United States
- Sponsor
- Tarix Pharmaceuticals
Neoplasms, Cancer
Safety of CHIR-258 (TKI258) in Advanced Solid Tumors
Phase I dose finding study in solid tumors.
- Conditions
- Neoplasms, Cancer, Tumors
- Trial name
- NCT01270906
- Testing
- CHIR-258 (TKI258)
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
The LUME-Lung3 study is in 2 parts: Run-in Phase I - Open label study to identify the Maximum Tolerated Dose of BIBF 1120 that can be added to standard first-line treatment with 3 weekly schedules of gemcitabine and cisplatin.
- Trial name
- NCT01346540
- Testing
- BIBF 1120
- Where
- 7 sites in Italy, Netherlands and 2 more
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Cancer
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose…
- Trial name
- NCT00306891
- Testing
- Cediranib, Cediranib 30 - 90 mg
- Where
- 4 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Anogenital Warts
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Investigation of systemic catechin exposure following topically administered Veregen® 15% ointment in patients with external genital and perianal warts and following oral intake of a standardized green tea beverage in healthy…
- Trial name
- NCT01490008
- Testing
- Veregen, Green Tea
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MediGene
Multiple Myeloma
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or…
- Trial name
- NCT02206425
- Testing
- Melphalan, Prednisone, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Metastatic Uveal Melanoma
FHD-286 in Subjects With Metastatic Uveal Melanoma
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral…
- Trial name
- NCT04879017
- Testing
- FHD-286
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Foghorn Therapeutics Inc.
Cancer, Lymphoma
Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors or lymphoma. Both a capsule and a tablet formulation will be evaluated.
- Trial name
- NCT00486135
- Testing
- XL147 (SAR245408)
- Where
- 4 sites in United States, Spain
- Volunteers
- 118 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.